Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Test
11 mai 2022 16h06 HE
|
Exagen Inc.
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Medicare Administrative Contractor (MAC) Noridian has...
Exagen Inc. Reports First Quarter 2022 Results
11 mai 2022 16h05 HE
|
Exagen Inc.
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2022. ...
Exagen Announces Five-Week Campaign for Lupus Awareness Month
01 mai 2022 12h00 HE
|
Exagen Inc.
SAN DIEGO, May 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a...
Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022
25 avr. 2022 16h05 HE
|
Exagen Inc.
SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2022,...
Exagen Inc. to Participate in Investor Summit Group’s Q2 Conference
20 avr. 2022 16h05 HE
|
Exagen Inc.
SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in Investor Summit Group’s Q2...
Exagen Inc. Expands In-Network Access with Evolutions Healthcare Systems
30 mars 2022 08h25 HE
|
Exagen Inc.
SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests have entered into an in-network...
Exagen Inc. Expands In-Network Benefit with Additional 22.7 Million Lives
22 mars 2022 16h06 HE
|
Exagen Inc.
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests will soon surpass 90 million lives as...
Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results
22 mars 2022 16h05 HE
|
Exagen Inc.
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year...
Exagen Announces New Rheumatoid Arthritis Scientific Advisory Board
16 mars 2022 16h05 HE
|
Exagen Inc.
SAN DIEGO, March 16, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the formation of its new Scientific Advisory Board (SAB)...
Exagen Inc. to Participate in the 2022 KeyBanc Capital Markets Life Sciences and MedTech Investor Forum
09 mars 2022 16h05 HE
|
Exagen Inc.
SAN DIEGO, March 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the KeyBanc Capital Markets Life...